Cardarine (GW-501516) 10 mg – 100 Capsules

Biochem Cardarine (GW-501516) 10 mg – 100 Capsules | PPARδ Agonist

Biochem Cardarine (GW-501516) 10 mg – 100 Capsules is an oral capsule product containing cardarine, also known as GW-501516 or GW1516, a synthetic compound developed for investigation of peroxisome proliferator-activated receptor delta (PPARδ) signaling.

This product contains 10 mg of cardarine per capsule, with 100 capsules per package, representing 1,000 mg (1 gram) of cardarine per package, based on the stated formulation.

Cardarine belongs to a class of compounds known as PPARδ agonists. These compounds interact with nuclear receptors involved in the regulation of lipid metabolism, fatty acid oxidation, energy utilization, and metabolic gene expression.

Although cardarine is frequently grouped with selective androgen receptor modulators (SARMs) in online discussions, cardarine is not a SARM.

Unlike androgen receptor modulators such as andarine (S-4), ostarine (MK-2866), and ligandrol (LGD-4033), cardarine primarily targets PPARδ rather than the androgen receptor.

PPARδ is a nuclear receptor expressed in numerous tissues, including skeletal muscle, liver, adipose tissue, and the cardiovascular system.

Activation of this receptor influences the transcription of genes associated with fatty acid transport, lipid utilization, and metabolic adaptation.

Cardarine was originally investigated for potential therapeutic applications involving dyslipidemia, metabolic disorders, and cardiovascular risk factors.

Early human studies examined selected metabolic endpoints, including lipid-related biomarkers. However, these findings did not establish long-term clinical safety or justify therapeutic use.

Development of GW-501516 was discontinued following serious safety concerns arising from animal carcinogenicity studies.

Long-term animal studies identified tumor development in multiple organs. The relevance of these findings to particular human exposures cannot be quantified reliably, but they represent a substantial unresolved safety concern.

Cardarine has not been established as a safe or effective treatment for obesity, diabetes, cardiovascular disease, dyslipidemia, muscle wasting, or athletic performance enhancement.

Claims that cardarine reliably increases endurance, accelerates fat loss, or improves exercise performance in humans are not supported by adequate clinical evidence.

Cardarine is prohibited in competitive sport under World Anti-Doping Agency rules.

The Biochem brand name does not independently establish pharmaceutical approval, manufacturing quality, analytical purity, or clinical suitability.

1. Activates Peroxisome Proliferator-Activated Receptor Delta

Cardarine was developed as a synthetic agonist of PPARδ, a nuclear receptor involved in regulating metabolic gene expression.

PPARδ influences pathways associated with fatty acid utilization, energy metabolism, and tissue-specific metabolic responses.

The biological consequences of receptor activation depend on tissue type, receptor expression, and physiological conditions.

2. Influences Fatty Acid Metabolism

PPARδ signaling contributes to the regulation of genes involved in fatty acid transport and oxidation.

Cardarine has been studied for its ability to influence these pathways in experimental systems.

However, changes in metabolic signaling do not independently establish clinically meaningful fat loss or improved metabolic health in humans.

3. Has Been Investigated in Lipid Metabolism Research

Early clinical development examined cardarine in relation to lipid metabolism and selected cardiovascular risk biomarkers.

Some short-term studies reported changes in lipid-related measurements.

These findings do not demonstrate that cardarine reduces cardiovascular events or provides a favorable long-term risk-benefit profile.

4. Has Been Investigated in Skeletal Muscle Metabolism

PPARδ signaling contributes to metabolic regulation in skeletal muscle.

Experimental studies have investigated the relationship between PPARδ activation, oxidative metabolism, and exercise-related adaptations.

Animal and laboratory findings cannot be assumed to establish endurance or athletic performance benefits in humans.

5. Is Pharmacologically Different From SARMs

Cardarine is frequently discussed alongside SARMs because of its appearance in similar online product categories.

However, its principal molecular target is PPARδ rather than the androgen receptor.

It is therefore more accurately classified as a PPARδ agonist, not a selective androgen receptor modulator.

6. Has Limited Human Pharmacokinetic and Clinical Evidence

Cardarine underwent early human clinical investigation, but comprehensive long-term safety and efficacy data are unavailable.

The pharmacokinetics of a particular commercial capsule formulation cannot be established solely from the compound name or stated strength.

Online claims concerning precise elimination half-life, optimal dosing, or predictable human performance effects should not be treated as validated clinical conclusions.

7. Has Serious Carcinogenicity-Related Safety Concerns

The most significant safety concern associated with GW-501516 is the development of tumors observed in long-term animal studies.

These findings contributed to the discontinuation of its clinical development.

There is insufficient evidence to establish a safe human exposure level or to exclude carcinogenic risk.

Cardarine has no established medical indication and no validated human therapeutic dosage. The 10 mg capsule strength identifies the requested product presentation, not a medically established or safe dose.

Step 1 – Oral Capsule Administration

Cardarine is presented in oral capsule form.

Following ingestion, the compound would need to be released from the capsule and absorbed through the gastrointestinal tract before producing systemic effects.

The absorption characteristics of this specific Biochem formulation have not been independently established.

Step 2 – Distribution to PPARδ-Expressing Tissues

Following systemic absorption, cardarine may distribute to tissues expressing PPARδ.

Relevant tissues include skeletal muscle, liver, adipose tissue, and other metabolically active organs.

The tissue distribution of this particular product has not been established.

Step 3 – Interaction With PPARδ

Cardarine interacts with PPARδ and promotes receptor-associated transcriptional signaling.

PPARδ belongs to the nuclear receptor family and regulates the expression of genes involved in metabolic processes.

Step 4 – Modulation of Metabolic Gene Expression

PPARδ activation can influence genes associated with fatty acid transport, oxidation, and energy metabolism.

The magnitude and clinical significance of these effects in humans remain uncertain.

Step 5 – Metabolism and Elimination

Following systemic exposure, cardarine undergoes metabolic processing and elimination.

Comprehensive human pharmacokinetic information for the requested Biochem capsule formulation is unavailable.

The Biochem Cardarine 10 mg capsule presentation includes the following characteristics:

• Cardarine (GW-501516) as the stated active compound.
• 10 mg per capsule.
• 100 capsules per package.
• 1,000 mg total stated active ingredient content.
• Oral capsule presentation.
• PPARδ agonist classification.
• Synthetic nonsteroidal chemical structure.
• Nuclear receptor interaction.
• Modulation of metabolic gene transcription.
• Investigation of fatty acid oxidation pathways.
• Investigation of lipid metabolism.
• Preclinical research involving skeletal muscle metabolism.
• Early clinical investigation involving metabolic biomarkers.
• No established human therapeutic indication.
• No validated safe human dosing regimen.
• Clinical development discontinued.
• Serious carcinogenicity findings in animal studies.
• Inadequately characterized long-term human safety.
• No established clinical benefit for fat loss or endurance.
• Prohibited status under WADA rules.
• Capsule excipients requiring confirmation.
• Identity, purity, and content uniformity requiring independent analytical verification.

The precise excipient composition, capsule appearance, manufacturing specifications, purity, and analytical content of Biochem Cardarine 10 mg have not been independently verified.

The stated package contains 100 capsules of 10 mg each. This description does not establish regulatory authorization, clinical safety, or suitability for human administration.

United States

Biochem Cardarine 10mg, Biochem GW501516 10mg, Cardarine 10mg 100 capsules, GW501516 100 capsules, Cardarine United States, Cardarine PPAR delta agonist, GW501516 compound, Cardarine molecular formula, Cardarine chemical structure, GW501516 PPARδ receptor activity, Cardarine pharmacology, Cardarine preclinical studies, GW501516 lipid metabolism, Cardarine fatty acid oxidation, Cardarine animal carcinogenicity findings, GW501516 safety concerns, Cardarine clinical evidence, Cardarine capsule specifications.

Canada

English: Biochem Cardarine 10mg Canada, GW501516 10mg Canada, Cardarine 100 capsules, Cardarine PPARδ agonist, peroxisome proliferator-activated receptor delta, Cardarine properties, GW501516 pharmacology, Cardarine molecular structure, GW501516 lipid metabolism, Cardarine preclinical research, GW501516 carcinogenicity studies, Cardarine safety information, Cardarine clinical evidence.

French: Biochem Cardarine 10 mg Canada, GW501516 10 mg, Cardarine 100 capsules, agoniste du PPAR delta, récepteur activé par les proliférateurs de peroxysomes, propriétés de la cardarine, pharmacologie du GW501516, structure moléculaire, métabolisme des lipides, oxydation des acides gras, études précliniques, résultats de cancérogénicité animale, informations de sécurité, données cliniques limitées.

United Kingdom

Biochem Cardarine 10mg UK, Cardarine GW501516 UK, Cardarine 100 capsules, PPAR delta agonist, GW501516 pharmacology, Cardarine chemical structure, PPARδ receptor activation, Cardarine preclinical studies, GW501516 lipid metabolism, Cardarine fatty acid oxidation, Cardarine animal carcinogenicity, GW501516 safety profile, Cardarine clinical evidence.

Germany

Biochem Cardarine 10 mg Deutschland, Cardarine GW501516, Cardarine 100 Kapseln, PPAR Delta Agonist, Cardarine Eigenschaften, GW501516 Wirkungsmechanismus, PPARδ Rezeptor, Cardarine Molekülstruktur, präklinische Studien, Fettstoffwechsel, Fettsäureoxidation, Tierstudien zur Karzinogenität, Sicherheitsinformationen, begrenzte klinische Daten.

France

Biochem Cardarine 10 mg France, Cardarine GW501516, Cardarine 100 gélules, agoniste du PPAR delta, propriétés de la cardarine, mécanisme d'action du GW501516, récepteur PPARδ, structure moléculaire, études précliniques, métabolisme lipidique, oxydation des acides gras, cancérogénicité animale, informations de sécurité, données cliniques limitées.

Spain

Biochem Cardarine 10 mg España, Cardarine GW501516, Cardarine 100 cápsulas, agonista PPAR delta, propiedades de la cardarina, mecanismo de acción del GW501516, receptor PPARδ, estructura molecular, estudios preclínicos, metabolismo lipídico, oxidación de ácidos grasos, carcinogenicidad en animales, información de seguridad, evidencia clínica limitada.

Italy

Biochem Cardarine 10 mg Italia, Cardarine GW501516, Cardarine 100 capsule, agonista PPAR delta, proprietà della cardarina, meccanismo d'azione GW501516, recettore PPARδ, struttura molecolare, studi preclinici, metabolismo lipidico, ossidazione degli acidi grassi, cancerogenicità negli animali, informazioni di sicurezza, dati clinici limitati.

Portugal

Biochem Cardarine 10 mg Portugal, Cardarine GW501516, Cardarine 100 cápsulas, agonista PPAR delta, propriedades da cardarina, mecanismo de ação do GW501516, recetor PPARδ, estrutura molecular, estudos pré-clínicos, metabolismo lipídico, oxidação de ácidos gordos, carcinogenicidade em animais, informações de segurança, evidência clínica limitada.

Netherlands

Biochem Cardarine 10 mg Nederland, Cardarine GW501516, Cardarine 100 capsules, PPAR delta agonist, eigenschappen van cardarine, werkingsmechanisme GW501516, PPARδ receptor, moleculaire structuur, preklinisch onderzoek, vetstofwisseling, vetzuuroxidatie, carcinogeniteit in dierstudies, veiligheidsinformatie, beperkte klinische gegevens.

Belgium

Biochem Cardarine 10 mg België, Cardarine 10 mg Belgique, Cardarine GW501516, Cardarine 100 capsules, PPAR delta agonist, agoniste du PPAR delta, eigenschappen van cardarine, propriétés de la cardarine, PPARδ receptor, récepteur PPARδ, preklinisch onderzoek, études précliniques, carcinogeniteit, cancérogénicité, veiligheidsinformatie.

Switzerland

Biochem Cardarine 10 mg Schweiz, Cardarine 10 mg Suisse, Cardarine GW501516, Cardarine 100 Kapseln, Cardarine 100 gélules, PPAR Delta Agonist, agoniste du PPAR delta, PPARδ Rezeptor, récepteur PPARδ, präklinische Studien, études précliniques, Fettstoffwechsel, métabolisme lipidique, Karzinogenität, cancérogénicité, Sicherheitsinformationen.

Austria

Biochem Cardarine 10 mg Österreich, Cardarine GW501516, Cardarine 100 Kapseln, PPAR Delta Agonist, Cardarine Eigenschaften, GW501516 Wirkungsmechanismus, PPARδ Rezeptor, Molekülstruktur, präklinische Forschung, Fettstoffwechsel, Fettsäureoxidation, Tierstudien zur Karzinogenität, Sicherheitsinformationen, begrenzte klinische Daten.

Sweden

Biochem Cardarine 10 mg Sverige, Cardarine GW501516, Cardarine 100 kapslar, PPAR delta agonist, cardarine egenskaper, GW501516 verkningsmekanism, PPARδ receptor, molekylstruktur, prekliniska studier, lipidmetabolism, fettsyraoxidation, cancerframkallande effekter i djurstudier, säkerhetsinformation, begränsade kliniska data.

Norway

Biochem Cardarine 10 mg Norge, Cardarine GW501516, Cardarine 100 kapsler, PPAR delta agonist, cardarine egenskaper, GW501516 virkningsmekanisme, PPARδ reseptor, molekylstruktur, prekliniske studier, lipidmetabolisme, fettsyreoksidasjon, kreftfunn i dyrestudier, sikkerhetsinformasjon, begrensede kliniske data.

Denmark

Biochem Cardarine 10 mg Danmark, Cardarine GW501516, Cardarine 100 kapsler, PPAR delta agonist, cardarine egenskaber, GW501516 virkningsmekanisme, PPARδ receptor, molekylstruktur, prækliniske studier, lipidmetabolisme, fedtsyreoxidation, kræftfund i dyreforsøg, sikkerhedsinformation, begrænsede kliniske data.

Finland

Biochem Cardarine 10 mg Suomi, Cardarine GW501516, Cardarine 100 kapselia, PPAR delta agonisti, cardariinin ominaisuudet, GW501516 vaikutusmekanismi, PPARδ reseptori, molekyylirakenne, prekliiniset tutkimukset, rasva-aineenvaihdunta, rasvahappojen hapettuminen, syöpälöydökset eläinkokeissa, turvallisuustiedot, rajallinen kliininen näyttö.

Poland

Biochem Cardari